Table IV.
Asthma medication and study referral breakdown by treatment group
| Medication Class | Specific Medication | Escitalopram | Placebo | ||
|---|---|---|---|---|---|
| Severity | Severity | ||||
| High (n=13) | Low (n=33) | High (n=16) | Low (n=37) | ||
| n (% on each medication) | |||||
| Short-acting beta2-agonist | Albuterol sulfate | 9 (69%) | 31 (94%) | 14 (88%) | 33 (89%) |
| Levalbuterol tartrate | 1 (8%) | 1 (3%) | 2 (13%) | 2 (5%) | |
| Both (Albuterol + Levalbuterol) | 3 (23%) | 0 | 0 | 2 (5%) | |
| Long-acting beta2-agonist | Salmeterol xinafoate | 0 | 1 (3%) | 0 | 1 (3%) |
| Combination medication | Fluticasone propionate/salmeterol xinafoate | 8 (62%) | 13 (39%) | 8 (50%) | 20 (54%) |
| Mometasone furoate/formoterol fumarate | 0 | 5 (15%) | 2 (13%) | 0 | |
| Budesonide/formoterol fumarate | 1 (8%) | 0 | 0 | 2 (5%) | |
| Inhaled corticosteroids | Beclomethasone dipropionate | 1 (8%) | 7 (21%) | 4 (25%) | 8 (22%) |
| Fluticasone propionate | 1 (8%) | 4 (12%) | 1 (6%) | 4 (11%) | |
| Leukotriene receptor antagonist | Montelukast | 4 (31%) | 7 (21%) | 4 (25%) | 6 (16%) |
| Zafirlukast | 0 | 0 | 0 | 1 (3%) | |
| Muscarinic receptor antagonist | Ipratropium bromide | 1 (8%) | 2 (6%) | 6 (38%) | 3 (8%) |
| Tiotropium bromide | 0 | 1 (3%) | 2 (13%) | 0 | |
| Referral Information | Escitalopram (n=46) | Placebo (n=53) | |||
| Community-Oriented Primary Care Clinics (COPC) Flyers | 19 (41%) | 19 (36%) | |||
| Hospital-affiliated Asthma Clinic | 17 (37%) | 14 (26%) | |||
| Free/Paid Media | 6 (13%) | 5 (9%) | |||
| Other Research Studies | 2 (4%) | 12 (23%) | |||
| Word-of-Mouth | 2 (4%) | 3 (6%) | |||
Note: 32% (n=99) of participants were on multiple medications in addition to their rescue inhaler.